Picture of Zelluna ASA logo

ZLNA Zelluna ASA Share Price

0.000.00%
no flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-9.62%
3m-22.41%
6m-10.05%
1yr-76.79%
Volume Change (%)
10d/3m-31.2%
Price vs... (%)
52w High-86.94%
50d MA-17.86%
200d MA-41.61%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-265.16%
Return on Equity-111.07%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Zelluna ASA EPS forecast chart

Profile Summary

Zelluna ASA, formerly Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The Company provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    December 31st, 2024
    Incorporated
    March 29th, 2011
    Public Since
    June 3rd, 2019
    No. of Employees
    12
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    no flag iconOslo Stock Exchange
    Shares in Issue
    3,440,606.1
    Blurred out image of a map
    Address
    Ullernchausseen 64, OSLO, 0379
    Web
    https://www.zelluna.com/
    Phone
    Auditors
    Ernst & Young AS

    ZLNA Share Price Performance

    Upcoming Events for ZLNA

    Zelluna ASA Annual Shareholders Meeting

    Q1 2025 Zelluna ASA Earnings Release

    Q1 2025 Zelluna ASA Earnings Call

    Q2 2025 Zelluna ASA Earnings Release

    Similar to ZLNA

    Picture of Arcticzymes Technologies ASA logo

    Arcticzymes Technologies ASA

    no flag iconOslo Stock Exchange

    Picture of Bergenbio ASA logo

    Bergenbio ASA

    no flag iconOslo Stock Exchange

    Picture of Circio Holding ASA logo

    Circio Holding ASA

    no flag iconOslo Stock Exchange

    Picture of Exact Therapeutics AS logo

    Exact Therapeutics AS

    no flag iconOslo Stock Exchange

    Picture of Lifecare ASA logo

    Lifecare ASA

    no flag iconOslo Stock Exchange

    FAQ